Preparation of Programmed Cell Death-Ligand 1 Antibody Nanoparticles Based on Nude Mouse Model and Its Therapeutic...

In this experiment, the advantages of both liposomes and polymer nanoparticles were used to synthesize adriamycin-loaded liposome-polymer nanoparticles and conjugate them with PD-L 1 antibody (referred to as PD-L 1 antibody nano particles). The nanoparticles were encapsulated with doxorubicin hydrochloride and the near-infrared dye DIR, and small animal imaging methods were used in animal experiments to evaluate the targeting and therapeutic effects. The results showed that the red fluorescence of doxorubicin hydrochloride entered the cells, and the red fluorescence of the PD-L1 antibody nanoparticles in the 4h group was better than that in the 2h group. The intracellular red fluorescence of PD-L1 antibody nanoparticles 4h group was stronger than that of free doxorubicin 4h group. Flow cytometry and confocal experiments showed that A549 cells took up more PD-L1 antibody nanoparticles. The results showed that the fluorescence intensity of the PD-L1 antibody nanoparticle group was significantly stronger than that of the nanoparticle group, and the tumor outline was clear, and the fluorescence intensity became stronger and stronger over time, indicating that the PD-L1 antibody nanoparticles were targeted. Has certain targeting capabilities. The PD-L1 antibody nanoparticles synthesized in this study are a good drug carrier targeting lung cancer tumor cells, which can be better taken up by A549 lung cancer cells, and can more effectively kill tumor cells, inhibit tumor growth, and wrap near-infrared dyes are more conducive to in vivo imaging of animals and are useful for observing the effects of targeted treatment of lung cancer.